Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
Recruiting · NCT04519619 · Observational (researchers observe without assigning treatment) · Lead sponsor: Bayer
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).
Who can take part
Inclusion criteria
- Diagnosis of NVG
- Patients who have received IVT-AFL treatment according to Japanese labeling.
Exclusion criteria
- Patients who are contraindicated based on approved label
- Diagnosis of other indication
Where it is running
1 location listed.
- Many locations - Multiple Locations, Japan